Mavitalon (Diltiazem Hydrochloride)

Diltiazem hydrochloride blocks L‑type calcium channels in the heart and blood vessels. By reducing calcium entry, it relaxes vascular smooth muscle, leading to vasodilation, and decreases the force of cardiac contraction, which together lower blood pressure and reduce the heart's oxygen demand during angina.

The appropriate dose of Mavitalon is individualized by the prescribing clinician based on the patient’s medical condition, response to therapy, and other medications. Dosage adjustments are made according to clinical guidelines and patient-specific factors.

Safety data for diltiazem hydrochloride in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mavitalon belongs to the calcium channel blocker class, which primarily causes vasodilation. Compared with ACE inhibitors or beta‑blockers, it may be preferred when a patient requires both blood pressure control and heart rate reduction, but the choice depends on individual clinical profiles and physician judgment.

Mavitalon should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from excess moisture and direct sunlight to maintain its stability and potency throughout its shelf life.

Mavitalon is taken orally, usually with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include significant bradycardia, severe hypotension, and heart block, which can be life‑threatening. Patients should be monitored for symptoms such as fainting, dizziness, or unusually slow heartbeats, and seek immediate medical attention if they occur.

Mavitalon is contraindicated in patients with known hypersensitivity to diltiazem or any component of the formulation, those with severe sinus node dysfunction without a pacemaker, and individuals with second‑ or third‑degree atrioventricular block unless a pacemaker is in place.